Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Q1 Revenues Rise on Sales of Wave Kits

NEW YORK, May 2 – Buoyed by strong sales of its genetic mutation testing kits, Transgenomic’s first quarter 2001 life science revenues rose 66 percent to $7.9 million, compared with $4.7 million in life sciences revenues for the previous-year quarter, the company said Wednesday.

The company computed this revenue increase based on life science product sales alone to reflect the fact that it sold its non-life sciences businesses at the end of the first quarter of 2000. Including all products, the company’s revenues rose 14 percent, from $6.9 million in the first quarter of 2000.

The Omaha, Neb-based company’s expenses for the quarter also rose to $6.3 million from $4.7 million for life sciences in the year-ago period, or $6.1 million in total first quarter 2000 expenses. 

R&D expenses rose to $2.1 million from $1.5 million for life sciences and $1.9 in total R&D  in the year-ago quarter. Sales, general, and administrative expenses also increased to $4.2 million for the quarter, compared to $3.1 million for life sciences and $3.5 million total in the first quarter of 2000.

“Transgenomic's first quarter results are continued evidence of the validation of our technology as an essential tool for the genomics community," Transgenomic CEO Collin D'Silva said in a statement. "During the quarter, over 35 percent of the units sold specifically for variation detection applications went to existing customers. In addition, sales remain strong into commercial accounts.”

During the quarter, the company installed its 500 th  WAVE nucleic acid fragment analysis system for DNA detection, and launched two new platform models for this system.

The company also announced earlier Wednesday that it had signed an agreement to acquire Annovis, a privately held San Diego company, for 1.9 million shares of Transgenomic common stock and $500,000 in cash. Annovis is a producer of producer of nucleic acid building blocks, fluorescent dyes and reagents, as well as oligomimetics, enhanced DNA and RNA molecules that are more stable and bioavailable than ordinary DNA and RNA molecules.

“Synergies between our companies provide us with another growth driver that should enhance our profitability in the near future and aid in our continuing push toward entering new markets by leveraging our global distribution infrastructure," said D'Silva. 

Transgenomic said it expected this acquisition to add $6 million in revenue in the remaining quarters of 2001 and more than $12 million of revenue in 2002. 

For the quarter, the company posted $1.1 million in losses, or 5 cents per share. This figure narrowed over the $2.8 million in life science losses, and $3.5 million in total net losses for the first quarter of 2000, and beat by a penny Wall Street’s expectations of 6 cents per share, based on a survey of two brokers conducted by FirstCall/Thomson Financial.  
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.